Skip to main content

Studer Orthotopic Ileal Neobladder

The Studer neobladder combines a detubularized, folded ileal reservoir with an intact isoperistaltic afferent limb and a urethral outlet. The Bern experience began in 1985. The ureters drain through freely refluxing ureteroileal anastomoses; the afferent limb is not a formal antireflux valve.[1][2]

Studer/Wiklund reconstruction accounted for 74% of procedures in a 2023 multicenter cohort of 732 men undergoing intracorporeal neobladder reconstruction. That describes the participating centers and population, not the worldwide proportion of all urinary diversions.[3]

Patient Selection​

Discuss conduit, continent cutaneous and orthotopic options with eligible patients. Selection depends on bowel suitability, kidney and liver function, urethral oncologic safety, sphincter function, ability to manage emptying and the patient's priorities.[4][5]

  • Ability to empty and catheterize: patients must understand scheduled emptying, recognize retention and be willing and physically able to perform intermittent catheterization if needed. An inability to manage these requirements is a major barrier to a continent diversion.
  • Renal and hepatic function: severe impairment limits the ability to handle the metabolic load of urine in bowel. The AUA guideline lists inadequate renal function, giving eGFR below 45 mL/min/1.73 m² as an example, among contraindications to continent diversion. EAU uses the broader category of severe impairment. Do not substitute a universal serum-creatinine cutoff for individualized assessment.[4][5]
  • Urethral outlet: verify a negative urethral margin before orthotopic diversion. Invasive urethral tumor requiring urethrectomy precludes a neobladder. Non-muscle-invasive disease in a preoperative prostatic-urethral or bladder-neck biopsy does not necessarily preclude it when the retained urethra is oncologically suitable; it changes counseling and surveillance.[4][5]
  • Other constraints: insufficient usable bowel, an uncorrectable urethral stricture or inability to catheterize may rule out reconstruction. EAU lists high-dose prior pelvic radiotherapy, complex urethral strictures and severe sphincter-related incontinence as relative contraindications requiring careful selection. Age alone is not an absolute exclusion.[4][5]

In women, a negative bladder-neck biopsy alone does not establish the safety of the final retained urethra. Assessment of the proximal urethral margin, together with preservation of an appropriate outlet, remains central.[6][4]

Anatomy and Construction​

The reservoir, afferent limb and urethral outlet have distinct functions:

ComponentConstruction and purpose
ReservoirThe distal ileal segment is opened along its antimesenteric border and folded in more than one plane to form a capacious reservoir. Detubularization reduces coordinated bowel contractions; it does not eliminate bowel muscle or guarantee safe storage pressures.
Afferent limbAn intact proximal ileal segment remains in continuity with the pouch and receives the ureters. Its length and orientation facilitate ureteral drainage, but reflux can occur.
Urethral outletA dependent, tension-free pouch-to-urethra anastomosis provides the route for emptying; continence also depends on the retained sphincter and storage/emptying behavior.

Published modifications vary in segment length, folding sequence and anastomotic technique. For example, Bianchi's modification uses approximately 40 cm for the reservoir and 15 cm for the afferent limb; the USC robotic technique describes a longer total segment. These are operative designs, not interchangeable fixed prescriptions or a guarantee against vitamin B12 deficiency.[7][8]

Studer orthotopic neobladderOriginal schematic · v2026-09-11 · Clinical review pending

A detubularized reservoir connects to the urethra, while a tubular afferent limb receives the ureters. Low-pressure storage alone does not establish continence or upper-tract safety; outlet competence, unobstructed drainage, emptying and surveillance matter. (Original WARWIKI schematic; see the figure source record and review limits.)

Operative framework​

  1. Confirm reach before isolation. Select a well-perfused ileal segment whose mesentery allows the reservoir to reach the urethra without tension or twisting. Preserve bowel and ureteral blood supply and avoid unnecessary loss of terminal ileum.
  2. Isolate the planned segment and restore bowel continuity. Retain the designated proximal afferent limb intact.
  3. Detubularize the reservoir segment. Open the planned distal bowel along the antimesenteric border and construct the posterior plate.
  4. Fold and close the reservoir. The Studer configuration uses cross-folding to create a rounded pouch. A generic W-pouch should not be relabeled Studer solely because it is made from ileum.
  5. Join the dependent pouch to the urethra. Obtain a tension-free, watertight anastomosis over drainage. The order of folding and urethral anastomosis differs among open and intracorporeal techniques.
  6. Implant the ureters in the afferent limb. Preserve periureteral tissue, spatulate adequately and avoid angulation or ischemia. Direct implantation is refluxing; an added valve is a separate modification.
  7. Check closure, drainage and orientation. Document ureteral stents, pouch drainage and the planned postoperative assessment before catheter removal.[7][8][2]

Fixation of the pouch to the levator ani and afferent limb to psoas was reported in Bianchi's 36-patient modification. It is not a universal Studer step, and that series does not establish superior function from fixation.[7]

Open and intracorporeal approaches​

Gill's 2002 report described the early completely intracorporeal laparoscopic experience. Subsequent robotic reports describe refinements in particular programs. A fall in operating time within one program should not be treated as the expected effect of robotic surgery in every setting.[9][8]

The 2024 systematic review and atlas of intracorporeal neobladders included 19 studies and nine techniques. It found substantial variation in reporting and no eligible randomized or comparative cohort studies comparing the techniques. Similar reported outcomes across separate series do not establish equivalence or a universally best configuration.[10]

Does a Formal Antireflux Mechanism Help?​

USC-STAR is the important randomized comparison: 484 patients were randomized to Studer or T-pouch reconstruction; 423 had baseline outcome data and 260 contributed the three-year renal endpoint. The remaining baseline cohort included 124 deaths and 39 patients without three-year renal data, so the renal result is not a complete 484-patient long-term assessment.[2]

Three-year outcomeStuderT-pouch
Mean eGFR change, mL/min/1.73 m²−6.4−6.6
Cumulative diversion-related secondary surgical intervention13%22%

The primary renal comparison was not statistically significant (p = 0.35); diversion-related reintervention was more frequent with T-pouch. Symptomatic UTI and overall late-complication rates did not differ significantly. Baseline renal function, age and urinary-tract obstruction were associated with renal deterioration. The trial did not demonstrate renal benefit from the formal antireflux design, and it should not be described as a proof of equivalence or of superiority of every refluxing technique.[2]

The earlier Cochrane review found the randomized diversion evidence limited and heterogeneous. Its search preceded USC-STAR, so it cannot substitute for this later trial or settle comparisons among contemporary designs.[11]

Emptying, Continence and Urodynamics​

A neobladder retains bowel smooth muscle but lacks the native bladder's coordinated detrusor emptying mechanism. Patients generally empty by relaxing the outlet and increasing abdominal pressure. They need an individualized schedule, including overnight emptying when necessary, and assessment of residual urine. Persistent incomplete emptying requires evaluation and often intermittent catheterization; it should not be expected to resolve merely with time.[5][1]

Define the outcome before quoting a continence rate. Daytime versus nighttime continence, no pads versus a safety pad, patient questionnaires versus clinician reports and follow-up duration can produce very different estimates.

EvidenceWhat it actually reports
Bern experience, 482 reconstructions accumulated during 1985–2005Reported one-year daytime and nighttime continence of 92% and 79%. This is a selected institutional experience accrued over 20 years, not 20-year follow-up of every patient.[1]
Multicenter intracorporeal cohort, 732 men with several designsAt 12 months, 86% daytime and 66% nighttime continence; these categories included 20% and 32% of patients using a safety pad. These are neither strict pad-free rates nor isolated Studer results.[3]
USC male neobladder questionnaire studyAmong respondents, only 22.3% reported no pads. The response rate was 68%, and results combined neobladder designs; they illustrate the effect of definitions and response selection.[12]

Nighttime leakage and the possibility of catheterization remain essential counseling topics. Selected long-term survivor series of Hautmann neobladders cannot be used to promise that Studer patients will eventually stop catheterizing or producing troublesome mucus.[13]

Urodynamics is useful when symptoms, poor emptying or concern about storage pressure require investigation. Do not use ranges assembled from small studies as normal values or safety thresholds. Capacity, compliance, pressure, residual urine, continence and upper-tract findings must be interpreted together; a large reservoir or an apparently satisfactory flow rate alone does not establish safe function.[14][5]

Complications and Metabolic Consequences​

Early risks include urine or bowel leak, infection, ileus, thromboembolism and other complications of cystectomy. Later problems include ureteroenteric or urethral-outlet obstruction, impaired emptying, infection, stones, hernias, metabolic acidosis and nutritional deficiency. Both the operation and long-term functional care influence risk.[1][15]

Large Hautmann series provide useful broader neobladder context but are not Studer-specific estimates. The 1,013-patient early-complication report and the 923-patient long-term report used different eligible populations and follow-up periods. Combining their percentages with tiny Studer survivor series creates a misleading single risk table.[16][17]

For example, Nam's report assessed 19 long-term survivors, although 50 patients had reached the ten-year interval from an original 108-patient cohort. Its six cases of renal atrophy and five cases of hydronephrosis identify important possible late problems; they do not establish those risks for all patients receiving a Studer reconstruction.[14]

  • Hyperchloremic metabolic acidosis: assess serum electrolytes and bicarbonate alongside kidney function. Requirements for alkali vary with urine contact, emptying and renal reserve; a supplementation percentage from another pouch series is not an expected Studer rate.
  • Vitamin B12 deficiency: risk may appear years after ileal surgery. Preserving some terminal ileum does not guarantee protection. EAU recommends annual vitamin B12 measurement after bowel diversion.[15]
  • Mucus: educate patients about the prescribed irrigation and drainage plan. Mucus obstruction, retention and stones remain possible in long-term follow-up; survivor-series observations do not justify stopping surveillance.
  • Renal assessment: routine monitoring includes serum creatinine/eGFR, electrolytes and appropriate upper-tract imaging. Historical concern about urinary creatinine clearance in a bowel reservoir must not be turned into a claim that serum creatinine is unusable or that all patients need scheduled nuclear GFR scans.[18][19]

See Renal function and metabolic surveillance, Vitamin B12 supplementation, Urinary acidifiers & alkalinizers, and Mucus management.

Quality of Life and Choice of Pouch​

An orthotopic reservoir avoids an external urine appliance but introduces different demands: scheduled emptying, possible leakage, mucus and potential catheterization. A conduit has its own stoma and appliance burdens. Neither provides universally better quality of life. Most comparative evidence is observational and is affected by selection, age, baseline health and the instrument used.[20][21]

In the 2016 meta-analysis of nonrandomized comparisons, the overall pooled quality-of-life difference was not statistically significant, although selected subgroup results favored neobladder. A 2022 review in women included only four studies and 283 patients; a nonsignificant result with wide confidence intervals does not prove the diversions equivalent.[20][22]

Choose the reservoir with the patient and an experienced reconstructive team. Current comparative evidence supports discussion of the Studer–T-pouch randomized result, but does not justify a table assigning similar renal function, continence and revision rates to every named neobladder.[2][10]

Long-Term Surveillance​

Separate functional follow-up from cancer surveillance, and continue functional assessment beyond the period of intensive oncologic imaging.[15][19]

DomainFollow-up focus
Kidney function and metabolic statusCreatinine/eGFR, electrolytes and bicarbonate; investigate deterioration rather than attributing it automatically to age. AUA recommends laboratory assessment every 3–6 months for the first 2–3 years after treatment and then annually, with additional testing as clinically needed.[19]
Upper tractImaging for obstruction, stones and other abnormalities, coordinated with cancer imaging. Select functional renal imaging when it answers a specific drainage or renal-function question.
Emptying and storageContinence, voiding pattern, residual urine, catheterization ability and symptoms of infection or high-pressure storage. Investigate new retention, recurrent infection or upper-tract change.
NutritionAnnual B12 measurement and evaluation of diarrhea, nutritional problems or unexplained anemia/neurologic symptoms.[15]
Retained urotheliumStage- and risk-appropriate cancer follow-up, including monitoring of the retained urethra. Urethral symptoms, bleeding or a high-risk history require investigation; one fixed cytology schedule is not appropriate for every patient.[19]
Self-careReview emptying, mucus management, hydration and access to urgent assessment for inability to drain, fever or new abdominal/flank pain.

See Also​

Videos​

The Modified Studer Ileal Neobladder
Neobladder (2014)

References​

1. Studer UE, Burkhard FC, Schumacher M, et al. Twenty years experience with an ileal orthotopic low pressure bladder substitute—lessons to be learned. J Urol. 2006;176(1):161–166. doi:10.1016/S0022-5347(06)00573-8.

2. Skinner EC, Fairey AS, Groshen S, et al. "Randomized trial of Studer pouch versus T-pouch orthotopic ileal neobladder in patients with bladder cancer." J Urol. 2015;194(2):433–439. doi:10.1016/j.juro.2015.03.101

3. Martini A, Falagario UG, Russo A, et al. "Robot-assisted radical cystectomy with orthotopic neobladder reconstruction: techniques and functional outcomes in males." Eur Urol. 2023;84(5):484–490. doi:10.1016/j.eururo.2023.04.009

4. American Urological Association / American Society of Clinical Oncology / Society of Urologic Oncology. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer. Amended 2024. Statements 13–14 and discussion, urinary diversion and urethral margins. Guideline PDF.

5. European Association of Urology. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. 2026. Disease management, section 6.7.5, urinary diversion. Guideline.

6. Stein JP, Penson DF, Wu SD, Skinner DG. "Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature." J Urol. 2007;178(3 Pt 1):756–760. doi:10.1016/j.juro.2007.05.013

7. Bianchi G, Sighinolfi MC, Pirola GM, Micali S. "Studer orthotopic neobladder: a modified surgical technique." Urology. 2016;88:222–225. doi:10.1016/j.urology.2015.11.020

8. Chopra S, de Castro Abreu AL, Berger AK, et al. "Evolution of robot-assisted orthotopic ileal neobladder formation: a step-by-step update to the USC technique." BJU Int. 2017;119(1):185–191. doi:10.1111/bju.13611

9. Gill IS, Kaouk JH, Meraney AM, et al. Laparoscopic radical cystectomy and continent orthotopic ileal neobladder performed completely intracorporeally: the initial experience. J Urol. 2002;168(1):13–18. doi:10.1016/S0022-5347(05)64821-5.

10. Piramide F, Turri F, Amparore D, et al. "Atlas of intracorporeal orthotopic neobladder techniques after robot-assisted radical cystectomy and systematic review of clinical outcomes." Eur Urol. 2024;85(4):348–360. doi:10.1016/j.eururo.2023.11.017

11. Cody JD, Nabi G, Dublin N, et al. "Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy." Cochrane Database Syst Rev. 2012;(2):CD003306. doi:10.1002/14651858.CD003306.pub2

12. Ahmadi H, Skinner EC, Simma-Chiang V, et al. "Urinary functional outcome following radical cystoprostatectomy and ileal neobladder reconstruction in male patients." J Urol. 2013;189(5):1782–1788. doi:10.1016/j.juro.2012.11.078

13. Hautmann RE, Volkmer B, Egghart G, et al. "Functional outcome and complications following ileal neobladder reconstruction in male patients without tumor recurrence: more than 35 years of experience from a single center." J Urol. 2021;205(1):174–182. doi:10.1097/JU.0000000000001345

14. Nam JK, Kim TN, Park SW, Lee SD, Chung MK. "The Studer orthotopic neobladder: long-term (> 10 yr) functional outcomes, urodynamic features, and complications." Yonsei Med J. 2013;54(3):690–695. doi:10.3349/ymj.2013.54.3.690

15. European Association of Urology. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. 2026. Follow-up, section 7.4, functional outcomes and complications. Guideline.

16. Hautmann RE, de Petriconi RC, Volkmer BG. "Lessons learned from 1,000 neobladders: the 90-day complication rate." J Urol. 2010;184(3):990–994. doi:10.1016/j.juro.2010.05.037

17. Hautmann RE, de Petriconi RC, Volkmer BG. "25 years of experience with 1,000 neobladders: long-term complications." J Urol. 2011;185(6):2207–2212. doi:10.1016/j.juro.2011.02.006

18. Broderick GA, Stone AR, deVere White R. Neobladders: clinical management and considerations for patients receiving chemotherapy. Semin Oncol. 1990;17(5):598–605. PubMed.

19. American Urological Association / American Society of Clinical Oncology / Society of Urologic Oncology. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer. Amended 2024. Statements 31–32 and discussion, laboratory follow-up and retained urethra. Guideline PDF.

20. Cerruto MA, D'Elia C, Siracusano S, et al. "Systematic review and meta-analysis of non-RCTs on HRQoL after radical cystectomy using validated questionnaires: better results with orthotopic neobladder versus ileal conduit." Eur J Surg Oncol. 2016;42(3):343–360. doi:10.1016/j.ejso.2015.10.001

21. Kern SQ, Speir RW, Tong Y, et al. "Longitudinal HRQoL after open radical cystectomy: comparison of ileal conduit, Indiana pouch, and orthotopic neobladder." Urology. 2021;152:184–189. doi:10.1016/j.urology.2020.12.036

22. Xing W, Zeng S, Xu Z, Xing S, Liu Q. "Comparison of HRQoL between ileal conduit diversion and orthotopic neobladder in women: a meta-analysis." Front Oncol. 2022;12:862884. doi:10.3389/fonc.2022.862884